Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YY-20394 (Linperlisib) in Advanced Solid Tumors
NCT04049929Phase 1Unknown
- Sponsor
- Yingli Pharma
- Start
- Aug 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of linperlisib in solid tumor (advanced stage), sponsored by Yingli Pharma. Primary endpoint: Adverse events evaluated by NCI CTCAE v5.0. Status: unknown.
02
Drugs
linperlisib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04049929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04049929.